Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

UCB Cares 001 844 599 2273


UCB Cares +18445992273
ucbcares@ucb.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

Recruiting

Open to: ALL

Age: 2.0 - 18.0

Medical Conditions

Spondylitis
Arthritis
Arthritis, Psoriatic
Spondylitis, Ankylosing
Arthritis, Juvenile
Enthesopathy


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to assess plasma bimekizumab concentrations following subcutaneous (sc) bimekizumab administration.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Mar 2025 Feb 2028

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Bimekizumab will be administered at pre-specified timepoints.

Intervention Arm Group : Bimekizumab;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Ja0005 40785
    Nottingham
  • Ja0005 40786
    Bristol
  • Ja0005 40783
    Manchester
  • Ja0005 40784
    Stroke-on-trent


The study is sponsored by UCB Biopharma SRL




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06668181
Last updated 05 June 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.